Skip to main content
Premium Trial:

Request an Annual Quote

Still a Gap

A new analysis finds that women are still less likely to win major research prizes than men, Nature News reports.

It adds that the gap has shrunk, but not closed. For the analysis, Lokman Meho from the American University of Beirut examined the recipients of 141 international research prizes between 2001 and 2020. As he reports in Quantitative Science Studies, he found an increase over time in female researchers' share of prestigious prizes, but that that share still lagged behind that of male researchers. For instance, women won 6 percent of prizes between 2001 and 2005 and then 19 percent between 2016 and 2020.

"We are moving in the right direction, although slowly," Meho tells Nature News.

Nature News adds that groups like the Royal Society UK, the American Geophysical Union, and others have taken measures to improve representation. But still, Hans Petter Graver, president of the Norwegian Academy of Science and Letters, which administers the Abel and Kavli prizes, tells it that the findings suggest such institutions need "to do more for diversity."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.